오가노이드 및 스페로이드 시장 : 유형, 용도 및 최종 용도별 - 세계 예측(2024-2032년)

Global Organoids and Spheroids Market size will record 19.1% CAGR from 2024 to 2032 due to advancements in biotechnology, particularly in 3D cell culture and bioengineering, coupled with the rising demand for personalized medicine. The influx of technologies is enabling precise disease modeling, drug testing, and tailored treatment approaches for enhancing therapeutic efficacy and patient outcomes.

With increasing applications across pharmaceutical research and regenerative medicine, organoids and spheroids offer innovative solutions to cater to the complexities of diseases, driving growth in both research and clinical settings globally. For instance, in January 2024, HUB Organoids HUB introduced the IntegriGut Screen by utilizing IBD patient-derived organoid monolayers PDO monolayers to provide crucial human data on epithelial barrier function.

The organoids and spheroids industry is classified into type, application, end-use, and region.

By end-use, the academic and research institutes segment will experience robust growth through 2032, attributed to the pivotal role in advancing biotechnological research. These institutions are driving innovations in 3D cell culture technologies for enhancing disease modeling and drug testing capabilities. With robust funding and collaborations with pharmaceutical companies, academic and research institutes are contributing significantly to therapeutic development and personalized medicine.

In terms of application, the organoids and spheroids market from the personalized medicine segment will witness substantial CAGR between 2024 and 2032, propelled by the tailored approach to treatment. Organoids and spheroids offer precise disease modeling and drug testing, which is crucial for developing patient-specific therapies. With advancements in biotechnology and increased adoption in pharmaceutical research, personalized medicine is also leveraging 3D cell culture models to optimize treatment outcomes, driving significant segment growth.

Asia Pacific organoids and spheroids market will demonstrate a decent CAGR between 2024 and 2032, spurred by increasing investments in biotechnology and pharmaceutical sectors. The robust research infrastructure and growing healthcare expenditure is fostering the adoption of advanced 3D cell culture technologies. With rising initiatives in drug discovery and personalized medicine, Asia Pacific will stand out as a key contributor to the industry growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Advancement in cell culture technologies
    • 3.2.1.2 Increase in demand for personalized medicine
    • 3.2.1.3 Rise in prevalence of chronic disease
    • 3.2.1.4. Technological advancement in 3 D spheroid
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Lack of robust disease models
    • 3.2.2.2 High cost of development and maintenance
• 3.3 Growth potential analysis
• 3.4 Technology landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Organoids
  • 5.2.1 By Type
    • 5.2.1.1 Neural organoids
    • 5.2.1.2 Hepatic organoids
    • 5.2.1.3 Intestinal organoids
    • 5.2.1.4 Other organoid type
  • 5.2.2 By Method
    • 5.2.2.1 General submerged method for organoid culture
    • 5.2.2.2 Crypt organoid culture techniques
    • 5.2.2.3 Air Liquid Interface (ALI) method
    • 5.2.2.4 Other organoid methods
  • 5.2.3 By Source
    • 5.2.3.1 Primary tissue
    • 5.2.3.2 Stem cells
• 5.3 Spheroids
  • 5.3.1 By Type
    • 5.3.1.1 Multicellular tumor spheroids
    • 5.3.1.2 Neurospheres
    • 5.3.1.3 Mammospheres
    • 5.3.1.4 Hepatospheres
  • 5.3.2 By Method
    • 5.3.2.1 Micropatterned plates
    • 5.3.2.2 Low cell attachment plates
    • 5.3.2.3 Hanging drop method
    • 5.3.2.4 Other spheroid methods
  • 5.3.3 By Source
    • 5.3.3.1 Cell line
    • 5.3.3.2 iPSCs derived cells

Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Developmental biology
• 6.3 Personalized medicine
• 6.4 Regenerative medicine
• 6.5 Disease pathology studies
• 6.6 Drug toxicity & efficacy testing

Chapter 7 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Pharmaceutical & biotechnology companies
• 7.3 Academic & research institutes
• 7.4 Hospital & diagnostic centers

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 STEMCELL Technologies
• 9.2 Corning Incorporated
• 9.3 Merck KGaA
• 9.4 Greiner Bi-One
• 9.5 InSphero Inc.
• 9.6 Promega Corporation
• 9.7 Thermo Fisher Scientific Inc.
• 9.8 Lonza Group Ltd.
• 9.9 Prellis Biologics
• 9.10 AMSBIO LLC